The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics.
The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents.
Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class driven by Novartis’ Cosentyx and Eli Lilly’s Talz have set a new benchmark for efficacy in moderate to severe psoriasis treatment with potential for safety improvement in comparison to the anti TNF drugs given their greater specificity in immune Suppression. MP Advisors expect the TNF class of drugs to lose share to the newer brands with improved clinical profiles in Psoriasis.
The market growth in psoriasis is driven by an upsurge in demand from new therapies in moderate to severe patient population which overshadows reduced pricing of branded TNF-α inhibitor and recent biosimilar launches. The psoriasis treatment market is facing increasing competitive pressure from a wave of biosimilar launches such as biosimilars of Janssen’s Remicade, and Amgen’s Enbrel with the impact of the headwinds expected to be more pronounced in the next few years.
Stelara has been an important growth driver of Janssen’s immunology franchise in recent years, with overall global sales doubling from $1.5bn in 2013 to more than $3.2bn in 2016. However Stelara has started to face steeper competition from the IL-17 drug class. A new head-to-head study report IL-17 products to demonstrate superior efficacy to Stelara for psoriasis.
Kyowa hakko Kirin
TSH Biopharm Corp
Table of Contents
Executive Summary 4 List of Figures 7 List of Tables 8
3. Psoriasis Market for Biosimilars 79 3.1. Introduction and Market Overview 79 3.2. Approved biosimilars 79 3.2.1. Approved biosimilars in the U.S. 79 3.2.2. Revenue Analysis for Biosimilars in U.S. 81 3.2.3. Approved biosimilars in the EU 81 3.3. Pipeline Analysis 83 3.3.1. Clinical development ‒ Humira (adalimumab) biosimilars 84 3.3.2. Clinical development ‒ Enbrel (etanercept) biosimilars 84 3.3.3. Clinical development ‒ Remicade (infliximab) biosimilars 85 3.4. Biosimilars deals and partnerships 86 3.5. Growth Drivers and Resistors for Biosimilars 87 3.5.1. Growth Drivers 87 3.5.2. Resistors 90 3.6. Competitive Landscape ‒ Approved Biosimilars in the U.S. and EU 94 3.7. Competitive Landscape – TNF α Inhibitors Biosimilars Pipeline 96 References: 98
List of Tables
Table 1: Common sub-types of psoriasis Table 2: Genes associated with psoriasis sU.S.ceptibility Table 3: Psoriasis types of treatments’ Table 4: Psoriasis treatment options Table 5: Psoriasis global assessment Table 6: Approved biologics for psoriasis Table 7: Enbrel – Drug profile Table 8: Plaque psoriasis clinical studies – Enbrel Table 9: Meta-analyses comparison of TNF-α inhibitors and ustekinumab Table 10: Remicade – drug profile Table 11: Plaque psoriasis clinical studies – Remicade Table 12: Humira – drug profile Table 13: Plaque psoriasis clinical studies – Humira Table 14: Stelara – drug profile Table 15: Plaque psoriasis clinical studies – Stelara Table 16: Cosentyx – drug profile Table 17: Plaque psoriasis clinical studies – Cosentyx Table 18: Taltz – drug profile Table 19: Plaque psoriasis clinical studies – Taltz Table 20: Siliq – drug profile Table 21: Plaque psoriasis clinical studies – Siliq Table 22: Tremfya – drug profile Table 23: Plaque psoriasis clinical studies – Tremfya Table 24: Key pipeline products for psoriasis Table 25: Plaque psoriasis clinical studies – Tildrakizumab Table 26: Plaque psoriasis clinical studies – Cimzia Table 27: Phase-II comparator trial - risankizumab vs. ustekinumab Table 28: Growth drivers and resistors for biologics for psoriasis Table 29: Annual per patient expenditure on biologics for psoriasis Table 30: Competitive landscape of approved biologics for psoriasis Table 31: Competitive landscape of pipeline biologics for psoriasis Table 32: Approved biosimilars for psoriasis in the U.S., 2017 Table 33: Approved biosimilars for psoriasis in the EU, 2017 Table 34: Adalimumab biosimilars pipeline for psoriasis, 2017 Table 35: Etanercept biosimilars pipeline for psoriasis, 2017 Table 36: Infliximab biosimilars pipeline for psoriasis, 2017 Table 37: Key biosimilars for psoriasis – Partnerships and Deals Table 38: Growth drivers and resistors for biosimilars for psoriasis Table 39: EMA and U.S. FDA - biosimilars approval guidance comparison Table 40: Competitive landscape – Approved biosimilars in the U.S. Table 41: Competitive landscape – Approved biosimilars in EU Table 42: Competitive landscape – TNF-α inhibitors biosimilars pipeline
List of Figures
Figure 1: Common areas of distribution of psoriasis Figure 2: Psoriasis coverage and distribution Figure 3: Proposed schema of the evolution of a psoriatic lesion Figure 4: Comorbidities associated with psoriasis Figure 5: Burden of psoriasis by countries Figure 6: Psoriasis management algorithm Figure 7: Therapeutic targets for biologics in psoriasis Figure 8: Biological effects of TNF- α Figure 9: Schematic configuration of dominant TNF- α inhibitors Figure 10: The structure and function of the cytokines IL-12 and IL-23 Figure 11: IL-17-induced signaling pathways Figure 12: IL- 17 and IL 23 in the pathogenesis of psoriasis Figure 13: Sales estimates for biologics in psoriasis in U.S., 2016-21 Figure 14: Sales estimates forTNF-α inhibitor biologics in psoriasis in U.S., 2016-21 Figure 15: Sales estimates forIL-inhibitor biologics in psoriasis in U.S., 2016-21 Figure 16: SWOT analysis ‒ Enbrel Figure 17: Overall sales analysis ‒ Enbrel Figure 18: SWOT analysis ‒ Remicade Figure 19: Overall sales analysis ‒ Remicade Figure 20: SWOT analysis ‒ Humira Figure 21: Overall sales analysis ‒ Humira Figure 22: SWOT analysis ‒ Stelara Figure 23: Overall sales analysis ‒ Stelara Figure 24: SWOT analysis ‒ Cosentyx Figure 25: Overall sales analysis ‒ Cosentyx Figure 26: SWOT analysis ‒ Taltz Figure 27: Overall sales analysis ‒ Taltz Figure 28: SWOT analysis ‒ Siliq Figure 29: SWOT analysis ‒ Tremfya Figure 30: Sales estimates for biosimilars in psoriasis in U.S., 2016-21 Figure 31: Projected Savings from biosimilars in the US
Write comment about above report:
Published By: MP Advisors
Did you find what you are/were looking for
If not, read below and browse through other relevant pages for similar market research
reports OR get in touch with us through the form/contact info in your right navigation
panel and well share relevant market report titles for you to explore.
We are on:
500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Upto 24 hrs - working days
Upto 48 hrs max - weekends and public holidays
Buy Any Report Avail 20% Discount. Coupon Code: DEC20
Connect for special KNOWLEDGE STORE Deals Subscription starts at $ 20K